News
05-19-2010, 12:10 AM
Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.
More... (http://www.news-medical.net/news/20100519/Generex-Biotechnologys-Phase-I-study-data-of-AE37-for-prostate-cancer-published.aspx)
More... (http://www.news-medical.net/news/20100519/Generex-Biotechnologys-Phase-I-study-data-of-AE37-for-prostate-cancer-published.aspx)